NCT04623801Active, not recruitingPhase 2
Laser Ablation of Papillary Thyroid Microcarcinoma
Pilot Study to Evaluate the Safety and Efficacy of Percutaneous Laser Ablation of Thyroid Papillary Microcarcinoma
Source: ClinicalTrials.gov · Last updated 10 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to explore whether percutaneous laser ablation (PLA) is a safe and effective alternative to removing papillary thyroid microcarcinoma (PTMC) with surgery.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 6 Nov 2020
- Start date
- 19 Oct 2020
- Primary completion date
- Oct 2026
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Thyroid cancer
- NCT number
- NCT04623801
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 10
- From 19 Oct 2020 to the primary completion date, Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Thyroid cancer that is non papillary thyroid cancer (PTC)
Other
- Thyroid lesion with \> 25% cystic component
- Lesion with US evidence of extrathyroidal extension through the thyroid capsule
- Clinical or ultrasonographic evidence of lymph node metastasis
- Pregnancy
Who the study is looking for
- Age ≥ 18 years
- Papillary thyroid cancer documented by
- (a) Bethesda VI cytology,
- (b) Bethesda III, IV, V, or VI cytology AND BRAF V600E mutation, or
- (c) Bethesda V cytology AND high risk ultrasonographic features documented by either the ATA high suspicion or TIRADS 5 nodule characteristics
- To ensure the majority of cases will be eligible based on criteria (a) or (b), we will enroll ≤ 2 patients based on criteria (c).
- Maximum diameter ≤ 13 mm
- Declined active surveillance
- The thyroid lesion must be primarily solid with ≤ 25% cystic compent
- No US evidence of extrathyroidal extension through the thyroid capsule
- No imaging evidence of lymph node metastasis
- Preserved contralateral vocal cord function prior to PLA
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.